fenofibrate has been researched along with Familial Combined Hyperlipidemia in 22 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fibrinogen in plasma was reduced from 3." | 5.29 | [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia]. ( Ceska, R; Haas, T; Kvasilová, M; Kvasnicka, J; Procházková, R; Sobra, J, 1996) |
| "Treatment with simvastatin was associated with significantly greater reduction of total cholesterol and low-density lipoprotein cholesterol (LDL-C), while the decrease in triglycerides was significantly greater in patients receiving fenofibrate." | 2.71 | Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. ( Chen, MF; Chen, WJ; Cheng, CC; Lee, YT; Lin, JW; Wang, TD, 2003) |
| "Fenofibrate, in contrast, was more effective on all triglyceride-rich lipoproteins in both the fasting and the postprandial state." | 2.71 | Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. ( Dierkes, J; Güttler, K; Luley, C; Westphal, S; Wiens, L, 2003) |
| "Atorvastatin was more efficient in the reduction of total cholesterol, whereas fenofibrate was more efficient in the reduction of triglycerides." | 2.70 | Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. ( Ceska, R; Malik, J; Melenovsky, V; Pisarikova, A; Poledne, R; Simek, J; Skrha, J; Stavek, P; Wichterle, D, 2002) |
| "Simvastatin was associated with statistically significantly greater (p < or = 0." | 2.68 | Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. ( Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W, 1995) |
| " Discontinuation attributed to any adverse events (4." | 2.48 | Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. ( Ding, Z; Guo, J; Hou, R; Li, C; Ma, N; Meng, F; Qin, Y; Wang, H, 2012) |
| "Fibrinogen in plasma was reduced from 3." | 1.29 | [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia]. ( Ceska, R; Haas, T; Kvasilová, M; Kvasnicka, J; Procházková, R; Sobra, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 15 (68.18) | 29.6817 |
| 2010's | 1 (4.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arca, M | 2 |
| Cambuli, VM | 1 |
| Montali, A | 2 |
| Sentinelli, F | 1 |
| Filippi, E | 1 |
| Campagna, F | 1 |
| Quagliarini, F | 1 |
| Antonini, R | 2 |
| Romeo, S | 1 |
| Baroni, MG | 1 |
| Guo, J | 1 |
| Meng, F | 1 |
| Ma, N | 1 |
| Li, C | 1 |
| Ding, Z | 1 |
| Wang, H | 1 |
| Hou, R | 1 |
| Qin, Y | 1 |
| Melenovsky, V | 2 |
| Malik, J | 2 |
| Wichterle, D | 2 |
| Simek, J | 2 |
| Pisarikova, A | 1 |
| Skrha, J | 1 |
| Poledne, R | 1 |
| Stavek, P | 1 |
| Ceska, R | 3 |
| Haas, T | 2 |
| Malik, M | 1 |
| Wang, TD | 1 |
| Chen, WJ | 1 |
| Lin, JW | 1 |
| Cheng, CC | 1 |
| Chen, MF | 1 |
| Lee, YT | 1 |
| Westphal, S | 1 |
| Wiens, L | 1 |
| Güttler, K | 1 |
| Dierkes, J | 1 |
| Luley, C | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 2 |
| Wray, R | 1 |
| Ooi, TC | 1 |
| Cousins, M | 1 |
| Ooi, DS | 1 |
| Nakajima, K | 1 |
| Edwards, AL | 1 |
| Grundy, SM | 1 |
| Vega, GL | 1 |
| Yuan, Z | 1 |
| Battisti, WP | 1 |
| Brady, WE | 1 |
| Palmisano, J | 1 |
| Koh, KK | 2 |
| Quon, MJ | 2 |
| Han, SH | 2 |
| Chung, WJ | 2 |
| Ahn, JY | 1 |
| Seo, YH | 1 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Yesilbursa, D | 1 |
| Serdar, A | 1 |
| Saltan, Y | 1 |
| Serdar, Z | 1 |
| Heper, Y | 1 |
| Guclu, S | 1 |
| Cordan, J | 1 |
| Ribas, V | 1 |
| Palomer, X | 1 |
| Roglans, N | 1 |
| Rotllan, N | 1 |
| Fievet, C | 1 |
| Tailleux, A | 1 |
| Julve, J | 1 |
| Laguna, JC | 1 |
| Blanco-Vaca, F | 1 |
| Escolà-Gil, JC | 1 |
| McKenney, JM | 1 |
| Farnier, M | 1 |
| Lo, KW | 1 |
| Bays, HE | 1 |
| Perevozkaya, I | 1 |
| Carlson, G | 1 |
| Davies, MJ | 1 |
| Mitchel, YB | 1 |
| Gumbiner, B | 1 |
| Christidis, DS | 1 |
| Liberopoulos, EN | 1 |
| Kakafika, AI | 1 |
| Miltiadous, GA | 1 |
| Cariolou, M | 1 |
| Ganotakis, ES | 1 |
| Elisaf, MS | 1 |
| Natoli, S | 1 |
| Micheletta, F | 1 |
| Riggi, S | 1 |
| Di Angelantonio, E | 1 |
| Antonini, TM | 1 |
| Diczfalusy, U | 1 |
| Iuliano, L | 1 |
| Rosenson, RS | 1 |
| Bruckert, E | 2 |
| De Gennes, JL | 1 |
| Malbecq, W | 1 |
| Baigts, F | 1 |
| Guérin, M | 1 |
| Dolphin, PJ | 1 |
| Turpin, G | 1 |
| Chapman, MJ | 1 |
| Sobra, J | 1 |
| Kvasnicka, J | 1 |
| Procházková, R | 1 |
| Kvasilová, M | 1 |
| Perreault, S | 1 |
| Hamilton, VH | 1 |
| Lavoie, F | 1 |
| Grover, S | 1 |
| Ellen, RL | 1 |
| McPherson, R | 1 |
| Brown, WV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patie[NCT00092157] | Phase 3 | 571 participants (Actual) | Interventional | 2002-05-01 | Completed | ||
| Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia[NCT00092573] | Phase 3 | 576 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
5 reviews available for fenofibrate and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.
Topics: Age Factors; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedul | 2012 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, | 2008 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Humans; Hydroxymethylglut | 1998 |
10 trials available for fenofibrate and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
Topics: Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL | 2002 |
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Topics: Adult; Atorvastatin; Autonomic Nervous System; Baroreflex; Cross-Over Studies; Fenofibrate; Heart Ra | 2003 |
Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
Topics: C-Reactive Protein; CD40 Antigens; CD40 Ligand; Double-Blind Method; Drug Therapy, Combination; Endo | 2003 |
Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia.
Topics: Administration, Oral; Adult; Atorvastatin; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; D | 2003 |
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Topics: Adult; Aged; Alanine Transaminase; Apolipoproteins; Aspartate Aminotransferases; Double-Blind Method | 2005 |
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Topics: Arteriosclerosis; Atorvastatin; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Thera | 2005 |
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Administration Schedule | 2006 |
Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Topics: Adult; alpha-Tocopherol; Atorvastatin; Biomarkers; Drug Combinations; Female; Fenofibrate; Heptanoic | 2007 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Fema | 1995 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
8 other studies available for fenofibrate and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
Topics: Adiponectin; Adult; Age Distribution; Atorvastatin; Biomarkers; Cholesterol, HDL; Family; Female; Fe | 2009 |
Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia.
Topics: Cholesterol; Dietary Fats; Diterpenes; Fasting; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipid | 2004 |
The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Topics: Adult; Aryldialkylphosphatase; C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fib | 2005 |
Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
Topics: Animals; Apolipoprotein A-II; Base Sequence; Cholesterol, HDL; Disease Models, Animal; Fenofibrate; | 2005 |
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvas | 2006 |
Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
Topics: Adult; Apolipoproteins B; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; | 1996 |
[The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Topics: Adult; Aged; Female; Fenofibrate; Fibrinogen; Heterozygote; Humans; Hyperlipidemia, Familial Combine | 1996 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |